StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.1
  1. Startseite
  2. /Verbindung

Levalbuterol Hydrochloride

HCID 123601
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
50293-90-8
Standard-SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.Cl
InChIKey
OWNWYCOLFIFTLK-YDALLXLXSA-N
Summenformel
C13H22ClNO3
Durchschnittliche Molmasse
275,77 g/mol
Monoisotopische Masse
275,12882124

Überblick

Levalbuterol Hydrochloride is the hydrochloride salt form of levalbuterol, a relatively selective sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol hydrochloride binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, thereby increasing the production of cyclic-3', 5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cyclic AMP concentrations also inhibit the release of inflammatory mediators from mast cells.

Namen und Bezeichner

Bevorzugter Name
Levalbuterol Hydrochloride
IUPAC
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydrochloride
Englischer Name
alfa1-[[1,1-Dimethylethylamino]methyl]-4-hydroxy-1-(S),3-benzene dimethanol Hydrochlorid
Summenformel
C13H22ClNO3
Molmasse
275.77168

Namen und Synonyme

Levalbuterol hydrochloride50293-90-8Levalbuterol HClXopenexLevosalbutamol Hydrochloride(-)-Salbutamol hydrochlorideAlbuterol hydrochloride, r-WDQ1526QJMNSC-759255Albuterol (r)-form hydrochlorideDTXSID20198296RefChem:56699
Weitere Namen anzeigen
ZopenexUnii-wdq1526qjmSalbutamol HydrochlorideSalbutamol (R)-Isomer HClSalbutamol Impurity 8 HClSalbutamol Impurity 14 HCl
Levalbuterol Inhalation SolutionDTXCID501207871,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, Hydrochloride,(alpha1R)-(R)-Albuterol Hydrochloride(R)-Salbutamol hydrochlorideSalbutamol (hydrochloride)R-albuterol hydrochloride(R)-4-(2-(tert-Butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol hydrochloride

Datenbank-Bezeichner

CAS
50293-90-8

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
72,7 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
5
Schwere Atome
18
Formalladung
0
Komplexität
227

Experimentelle und physikochemische Eigenschaften

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section158.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
169 · 169-171°C
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: ≥15mg/mL
Aggregatzustand
powder
Farbe
white to tan
Wasserlöslichkeit
2 O: · H2O: ≥15mg/mL
InChI
InChI=1/C13H21NO3.ClH/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;/h4-6,12,14-17H,7-8H2,1-3H3;1H/t12-;/s3
InChIKey
OWNWYCOLFIFTLK-ZLBVLXFENA-N
SMILES
c1(CO)cc([C@@H](O)CNC(C)(C)C)ccc1O.Cl |&1:5,r|

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 1 Eintrag

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 4 Einträge

LEVALBUTEROL HYDROCHLORIDE

beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]

LEVALBUTEROL INHALATION SOLUTION

Adrenergic beta2-Agonists [MoA]; beta2-Adrenergic Agonist [EPC]

Verwendung und Herstellung

UsesFor symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
Anwendungen · 2 Einträge

BeschreibungSalbutamol is an agonist of the β2-adrenergic receptor (β2-AR; Kd = 759 nM in a radioligand binding assay using CHO cells expressing the human receptor). It is selective for β2-ARs over β1- and β3-ARs (Kds = 46.8 and 21.9 μM, respectively). Salbutamol (25-50 μg/kg, i.v.) reduces acetylcholine-induced bronchospasm in anesthetized guinea pigs. It also reduces response of bronchial muscle to efferent vagal stimulation in anesthetized cats and dogs when administered at doses ranging from 1 to 2.5 and 10 to 20 μg/kg, respectively. Nebulized salbutamol reduces transpulmonary pressure in recurrent airway obstruction-affected horses (EC50 = 39.7 μg). Formulations containing salbutamol have been used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

VerwendenThe R-enantiomer

Vor- und nachgelagerte Produkte

Zugehörige Reaktionen

4
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1078016
HRID 1078016als Produktuspto-grants-1996_08
Reaktionsgleichung von HRID 1455721
HRID 1455721als Produktals Eduktuspto-grants-2009_01
Reaktionsgleichung von HRID 2375770
HRID 2375770als Eduktuspto-grants-2008_12
Reaktionsgleichung von HRID 2375771
HRID 2375771als Eduktuspto-grants-2008_12

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
PubChem CID
123601
DTXSID
DTXSID20198296
ChEMBL
CHEMBL1201061
UNII
WDQ1526QJM
EC Number
627-135-3
Toxicity DataLD<sub>50</sub>=1100 mg/kg (orally in mice)

Sicherheitsdaten

wgk
3
hs_code
2922504500
risk_code
22-37/38-41
hazard_code
Xn
safety_code
26-39
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Acute Tox. 4 OralEye Dam. 1Skin Irrit. 2STOT SE 3

Vorgelagerte Rohstoffe

2-Methyl-2-propanaminHydrogenbromidMethyl-5-acetylsalicylatDimethylsulfid-BoranPalladiumdihydroxid